{
    "nct_id": "NCT03647488",
    "official_title": "Phase II Multicenter Randomized Two-arm Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Pretreated Adult Patients With EGFR Wild-type ALK Rearrangement Negative Advanced/Metastatic Non-small Cell Lung Cancer",
    "inclusion_criteria": "* Histologically confirmed locally advanced/metastatic (stage IIIB/IV), EGFR wild-type, ALK rearrangement negative, non-small cell lung cancer\n* Subject had demonstrated progression following one prior platinum doublet and one prior PD-(L)1 checkpoint inhibitor (either alone or in combination, the most recent treatment regimen must have contained a PD-(L)1 checkpoint inhibitor)\n* Subjects must be candidates for single agent docetaxel\n* Subjects must have at least one lesion evaluable by RECIST 1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with a MET inhibitor or HGF (Hepatocyte growth factor) targeting therapy\n* Any untreated central nervous system (CNS) lesion\n* Use of any live vaccines against infectious diseases within 12 weeks of initiation of study treatment.\n\nOther protocol-defined inclusion/exclusion criteria might apply.",
    "miscellaneous_criteria": ""
}